MedTrace Logo

A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence

NCT03945799 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2022-08-31

No results posted yet for this study

Summary

To assess the primary effects and safety of Anlotinib in HCC patients at high risk of post surgery recurrence.

Conditions

Interventions

DRUG

Anlotinib Hydrochloride

Anlotinib: 12mg QD PO d1-14, 21 days per cycle, 8 cycles.

Sponsors & Collaborators

  • Shulan (Hangzhou) Hospital

    collaborator OTHER

  • West China Hospital

    collaborator OTHER

  • Huashan Hospital

    collaborator OTHER

  • Third Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • The First Hospital of Jilin University

    collaborator OTHER

  • Tianjin First Central Hospital

    collaborator OTHER

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    collaborator OTHER

  • Zhejiang University

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-22
Primary Completion
2022-06-25
Completion
2022-06-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03945799 on ClinicalTrials.gov